RxDoctor Payments DataLook up a doctor →

David Brown, MD

Ophthalmology · Houston, TXNPI 1548368509

Payments from drug & device makers

$51,664,920in general payments, 2019–2025

Across 4,334 payments — averaging $11,921 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$26.3M
  • Genentech, Inc.$13M
  • Roche TCRC, Inc.$4.8M
  • Regeneron$3.2M
  • Bayer$1.1M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$987K
  • plus $2.2M from 42 others
$53,945in research payments, 2019–2025

Across 21 payments — averaging $2568.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis Pharma AG$19K
  • Regeneron$18K
  • Ocular Therapeutix, Inc.$9K
  • Novartis$5K
  • Boehringer Ingelheim International GmbH$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis58$26,322,872
Genentech, Inc.799$13,019,540
Roche TCRC, Inc.368$4,785,567
Regeneron1,669$3,249,969
Bayer393$1,128,995
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)333$987,115
AstraZeneca6$582,296
Apellis Pharmaceuticals, Inc.116$358,982
Boehringer Ingelheim29$319,933
E.r. Squibb & Sons, L.L.C.2$146,401
Optos PLC20$95,480
Topcon Healthcare, Inc.11$95,063
Boehringer Ingelheim International GmbH16$77,923
Kyowa Kirin, Inc.21$64,250
Janssen Research & Development, LLC18$63,893
Novartis Pharma AG15$58,502
Ocular Therapeutix, Inc.21$36,282
Amgen(2 entities)7$33,126
Boehringer Ingelheim Pharma GmbH & Co.kg106$32,162
Celltrion, Inc.4$31,320
Grifols, S.A.12$29,200
Sanofi US Services Inc.2$26,923
AbbVie(2 entities)56$24,986
Hoffmann-la Roche Limited14$20,510
Hexal AG4$17,640
Regeneron Healthcare Solutions, Inc.62$10,618
Astellas Pharma Global Development3$10,100
Kowa Research Institute, Inc.4$6,000
Boehringer Ingelheim Finland Ky37$5,195
Biogen30$4,282
Samsung Bioepis Co., Ltd.1$3,900
Genentech USA, Inc.26$3,475
Carl Zeiss Meditec, Inc.1$2,528
Eyepoint US, Inc.4$2,321
Apotex Inc.1$2,000
Harrow Eye, LLC4$1,667
Optos, Inc.2$1,042
Astellas Pharma US Inc23$647
Carl Zeiss Meditec USA, Inc.9$553
Heidelberg Engineering, Inc.4$398
Alcon3$251
Coherus Oncology, Inc.3$201
Johnson & Johnson(2 entities)11$200
Mckesson Specialty Care Distribution, LLC1$182
Cardinal Health 108 LLC1$136
US Oncology Corporate, Inc.2$135
ASD Specialty Healthcare, LLC1$134
Medinc Of Texas1$29

How this compares

$51,664,920 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024
$7,407,084
Medicare patients
964
Services billed
37,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →